Fig. 2
In vitro PS-mediated macrophage uptake and in vivo biodistribution. (A) CLSM images of RAW 264.7 cells cultured with NVRBD-MLipo or NVRBD-MLipo (+) for 4 h with or without PS treatment. (B) FCM analysis of uptake level of nanovaccines. RAW 264.7 cells were treated with NVRBD-MLipo or NVRBD-MLipo (+) as described in (A). (C) The uptake level of nanovaccines (n = 3). RAW 264.7 cells were treated with NVRBD-MLipo or NVRBD-MLipo (+) as described in (A). (D) The in vivo fluorescence imaging of mice immunized with various groups via inhalation (nebulization, N) or subcutaneous (Sc) injection (n = 3). Ex vivo fluorescence (E) and immunofluorescence (F) imaging of lungs at 12 h post vaccination (n = 3). (G) FCM analysis of various groups uptake in AMs at 12 h post vaccination (n = 3). Data expressed as means ± SD. **p < 0.01